Dosimertinib-d5 (mesylate)_product_DataBase

Bioactivity	Dosimertinib-d5 (mesylate) is a potent and orally active EGFR inhibitor. Dosimertinib-d5 (mesylate) decreases the expression of p-EGFR and p-ERK protein levels. Dosimertinib-d5 (mesylate) shows antiproliferative and anti-tumor activity. Dosimertinib-d5 (mesylate) has the potential for the research of non-small-cell lung cancer (NSCLC)[1].
Invitro	Dosimertinib mesylate (compound 2h) (1, 10, 100, 100 nM; 2h) 以剂量依赖性方式降低 p-EGFR 和 p-ERK 蛋白水平[1]。 Cell Proliferation Assay[1] Cell Line:
In Vivo	Dosimertinib mesylate (0.75、1.5、3 mg/kg；口服，每天一次，持续 24 天) 在小鼠体内显示出抗肿瘤活性[1]。 Animal Model:
Name	Dosimertinib-d5 (mesylate)
Formula	C29H32D5N7O5S
Molar Mass	600.74
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Meng Y, et al. Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer. J Med Chem. 2021 Jan 28;64(2):925-937.

PeptideDB